Patent Application
20250161281
The present disclosure relates to inhibitors of Emopamil-Binding Protein (EBP), and pharmaceutically acceptable salts thereof, compositions of these compounds, processes for their preparation, their use in the treatment of diseases, their use in optional combination with a pharmaceutically acceptable carrier for the manufacture of pharmaceutical preparations, the use of the pharmaceutical preparations in the treatment of diseases, and methods of treating diseases comprising administering the EBP inhibitor to a warm-blooded animal, especially a human.
Emopamil-Binding Protein (EBP) is a Δ8-Δ7 sterol isomerase enzyme which isomerizes the double bond in sterol molecules, moving the double bond from the 8-9 position to the 7-8 position. Specifically, EBP converts either zymostenol to lathosterol, or zymosterol to dehydrolathosterol, during the biosynthesis of cholesterol (Silve et al., 1996, J Biol Chem. 271 (37), 22434-22440). It has been shown that an accumulation of 8-9 unsaturated sterols activates oligodendrocyte formation and remyelination (Hubler et al., 2019, Nature 560 (7718), 372-376).
Myelin is lipid-based molecule which forms protective layers (myelin sheathes) around nerve cell axons and insulates the axons. Demyelinating diseases, or myelin-related diseases, are a result of these myelin sheathes being damaged, degraded, or reduced in thickness. The loss of the myelin sheathes disrupts the electronic signals from the brain and can lead to nerve damage, vision loss, numbness, muscle weakness, cognitive decline, loss of motor functions, and other similar symptoms. In some myelin-related diseases, such as multiple sclerosis, a subject's immune system targets and breaks down their own myelin sheathes. The ability to repair and regenerate the myelin sheathes is key to treating these myelin-related diseases. Due to its function converting 8-9 sterols, inhibition of EBP is a potential target for activating remyelination, as its inhibition leads to an increase of these 8-9 sterol starting materials (Theodoropoulous et al, 2020, J. Am. Chem. Soc., 142, (13), 6128-6138).
In addition to its role in remyeliniation, EBP has also been shown to be a key enzyme in certain colorectal cancers due to the reduction in essential lipids such as cholesterol (Theodoropoulous et al, 2020, J. Am. Chem. Soc., 142, (13), 6128-6138).
Thus, there is a need for EBP inhibitors as potential therapeutic agents for treating diseases or disorders that are responsive to EBP inhibition.
The present disclosure provides compounds that are EBP inhibitors. In a first aspect, the present disclosure relates to compounds having the Formula I:
Another aspect of the disclosure relates to pharmaceutical compositions comprising compounds of Formula (I) or pharmaceutically acceptable salts thereof, and a pharmaceutical carrier.
In yet another aspect, the present disclosure provides a method of treating a disease or disorder that is responsive to inhibition of EBP in a subject comprising administering to said subject an effective amount of at least one compound described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method for treating multiple sclerosis. In some embodiments, the present disclosure provides a method for promoting myelination in a subject with a myelin-related disorder.
Another aspect of the present disclosure relates to the use of at least one compound described herein or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease or disorder responsive to inhibition of EBP. Also provided is a compound described herein or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder responsive to inhibition of EBP.
The present disclosure provides compounds and pharmaceutical compositions thereof that may be useful in the treatment of diseases or disorders through mediation of EBP function/activity, such as multiple sclerosis or other myelin-related disorders. In some embodiments, the compounds of present disclosure are EBP inhibitors.
In a first embodiment, the present disclosure provides a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
In a second embodiment, the compound of the present disclosure is represented by Formula (II):
or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (II) are as defined in the first aspect or the first embodiment above.
In a third embodiment, the compound of the present disclosure is represented by Formula (IIA) or (IIB):
or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (IIA) and (IIB) are as defined in the first aspect or the first or second embodiment above.
In a fourth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R3 is selected from the group consisting of phenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrazolopyridinyl, pyrazolopyridinyl, benzotriazolyl, furanyl, oxadiazolyl, imidazopyridinyl, thiophenyl, thiazoyl, triazoyl, and indoyl, each of which is optionally substituted with one to three R5; and the remaining variables are as described in the first aspect or the first, second, or third embodiment. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R3 is selected from the group consisting of phenyl, pyrazolyl, imidazolyl, oxazolyl, pyridinyl, pyrazolopyridinyl, pyrazolopyridinyl, benzotriazolyl, furanyl, oxadiazolyl, imidazopyridinyl, and thiophenyl, each of which is optionally substituted with one to three R5; and the remaining variables are as described in the first aspect or the first, second, or third embodiment.
In a fifth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
each of which is optionally substituted with one to three R5; or R3 is presented by the following formula:
each of which is optionally substituted with one or two R6; and the remaining variables are as described in the first aspect or the first, second, third, or fourth embodiment or any alternative embodiments described therein. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
each of which is optionally substituted with one to three R5; or R3 is presented by the following formula:
each of which is optionally substituted with one or two R6; and the remaining variables are as described in the first aspect or the first, second, third, or fourth embodiment or any alternative embodiments described therein.
In a sixth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R3 is selected from the group consisting of phenyl, pyrazolyl, imidazolyl, oxazolyl, and pyridinyl, each of which is optionally substituted with one to three R5; and the remaining variables are as described in the fourth embodiment.
In a seventh embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
each of which is optionally substituted with one or two R5; or R3 is presented by the following formula:
each of which is optionally substituted with one or two R6; and the remaining variables are as described in the fifth embodiment.
In an eighth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
and the remaining variables are as described in the fifth embodiment. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof. R3 is represented by the following formula:
and the remaining variables are as described in the fifth embodiment.
In a ninth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
and the remaining variables are as described in the fifth embodiment.
In a tenth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, wherein R5, for each occurrence, is independently halo, —OR5a, C1-6alkyl, 4 to 7-membered monocyclic heterocyclyl, or phenyl, wherein the C1-6alkyl is optionally substituted with —OR5a or halo, and wherein the 5- to 6-membered monocyclic heteroaryl is optionally substituted with C1-3alkyl; and R6 is C1-3alkyl; and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment or any alternative embodiments described therein. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, wherein R5, for each occurrence, is independently halo, —OR5a, C1-6alkyl, 4 to 7-membered monocyclic heterocyclyl, or phenyl, and wherein the C1-6alkyl are each optionally substituted with —OR5a; and R6 is C1-3alkyl; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment. In a further alternative embodiment, R5, for each occurrence, is independently —F, —Cl, —CH3, —CH2CH3, —CF3, —OCHF2, —OCH3, —CH2OCH3, tetrahydropyranyl, phenyl, pyridinyl; and R6 is —CH3, optionally, wherein R5 is represented by the following formula:
and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth embodiment or any alternative embodiments described therein.
In an eleventh embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 together with the nitrogen atom from which they are attached form a 4 to 9 membered heterocyclyl optionally substituted with one to three R4; and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment or any alternative embodiments described therein.
In a twelfth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R1 and R2 together with the nitrogen atom from which they are attached form a 4 to 6-membered monocyclic saturated heteterocyclyl or a 8 to 9 membered bicyclic heterocyclyl, each of which is optionally substituted with one to three R4; and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment or any alternative embodiments described therein.
In a thirteenth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R1 and R2 together with the nitrogen atom from which they are attached form a group represented by the following formula:
each of which is optionally substituted with one to three R4; and the remaining variables are as described in the twelfth embodiment or any alternative embodiments described therein. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R1 and R2 together with the nitrogen atom from which they are attached form a group represented by the following formula:
each of which is optionally substituted with one to three R4; and the remaining variables are as described in the twelfth embodiment or any alternative embodiments described therein.
In a fourteenth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 together with the nitrogen atom from which they are attached form a group represented by the following formula:
and the remaining variables are as described in the thirteenth embodiment or any alternative embodiments described therein. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 together with the nitrogen atom from which they are attached form a group represented by the following formula:
and the remaining variables are as described in the thirteenth embodiment or any alternative embodiments described therein.
In a fifteenth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R1 is Het, —C1-3alkyl-Het, —C1-3alkyl-C3-6cyclolkyl, C3-6cycloalkyl or C1-6alkyl, wherein the C3-6cycloalkyl and the C1-6alkyl are each optionally substituted with one or two R4; R2 is H or C1-3alkyl; Het is a 4 to 6 membered monocyclic saturated heterocyclyl or 6 to 7 membered bicyclic saturated heterocyclyl, wherein the 4 to 6 membered monocyclic saturated heterocyclyl and 6 to 7 membered bicyclic saturated heterocyclyl contain one oxygen ring atom and are each optionally substituted with one or two R4; and R4, for each occurrence, is independently —OR4a, halo, or C1-3alkyl, wherein the C1-3alkyl is optionally substituted by —OR4a; R4a is H or C1-3alkyl.; and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment or any alternative embodiments described therein. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R1 is Het, —C1-3alkyl-Het, C3-6cycloalkyl or C1-6alkyl, wherein the C3-6cycloalkyl and the C1-6alkyl are each optionally substituted with one or two R4; Het is a 4 to 6 membered monocyclic saturated heterocyclyl or 6 to 7 membered bicyclic saturated heterocyclyl, wherein the 4 to 6 membered monocyclic saturated heterocyclyl and 6 to 7 membered bicyclic saturated heterocyclyl contain one oxygen ring atom and are each optionally substituted with one or two R4; R4, for each occurrence, is independently-OH, halo or C1-3alkyl; R2 is H or C1-3alkyl; and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, or tenth embodiment or any alternative embodiments described therein.
In a sixteenth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, Het is oxetanyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, 2-oxaspiro[3.3]heptanyl, or 5-oxabicyclo[2.1.1]hexanyl, each of which is optionally substituted with one R4; and the remaining variables are as described in the fifteenth embodiment or any alternative embodiments described therein. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, Het is oxetanyl, tetrahydro-2H-pyranyl, or 5-oxabicyclo[2.1.1]hexanyl, each of which is optionally substituted with one R4; and the remaining variables are as described in the fifteenth embodiment or any alternative embodiments described therein.
In a seventeenth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R1 is represented by the following formula:
each of which is optionally substituted with one or two R4; and the remaining variables are as described in the fifteenth embodiment or any alternative embodiments described therein. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R1 is represented by the following formula:
each of which is optionally substituted with one or two R4; and the remaining variables are as described in the fifteenth embodiment or any alternative embodiments described therein.
In an eighteenth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R1 is represented by the following formula:
and the remaining variables are as described in the fifteenth embodiment or any alternative embodiments described therein. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R1 is represented by the following formula:
and the remaining variables are as described in the fifteenth embodiment or any alternative embodiments described therein.
In a nineteenth embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R2 is H or —CH3; and the remaining variables are as described in the fifteenth, sixteenth, seventeenth, or eighteenth embodiment or any alternative embodiments described therein. In an alternative embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, R2 is H; and the remaining variables are as described in the fifteenth, sixteenth, seventeenth, or eighteenth embodiment or any alternative embodiments described therein.
In one embodiment, for the compounds of Formula (I), (II), (IIA), or (IIB), or a pharmaceutically acceptable salt thereof, each R4, for each occurrence, is independently —F, —CH3, —CH2CH2OCH3, —CH2OH, —OH, or —OCH3; and the remaining variables are as described in the first aspect or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, fifteenth, sixteenth, seventeenth, eighteenth, or ninteenth embodiment or any alternative embodiments described therein.
In a twentieth embodiment, the compound of the present disclosure is represented by Formulas (III) or (IV):
or a pharmaceutically acceptable salt thereof, wherein:
In a twenty-first embodiment, for the compounds of Formula (III) or (IV), or a pharmaceutically acceptable salt thereof, Het is oxetanyl, tetrahydro-2H-pyranyl, or 5-oxabicyclo[2.1.1]hexanyl, each of which is optionally substituted with one R4;
Ring A is
each of which is optionally substituted with one to two R4;
each of which is optionally substituted with one or two R5;
each of which is optionally substituted with one or two R6; and the remaining variables are as described in the twentieth embodiment.
In a twenty-second embodiment, for the compounds of the formula (III) or (IV), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
and the remaining variables are as described in the twentieth or twenty-first embodiment.
In a twenty-third embodiment, for the compounds of Formula (III) or (IV), or a pharmaceutically acceptable salt thereof, Het is represented by the following formula:
and the remaining variables are as described in the twentieth, twenty-first, or twenty-second embodiment.
In a twenty-fourth embodiment, for the compounds of Formula (III) or (IV), or a pharmaceutically acceptable salt thereof, R4, for each occurrence, is independently —CH3, —OH, or F; and the remaining variables are as described in the twentieth, twenty-first, twenty-second, or twenty-third embodiment.
In a twenty-fifth embodiment, for the compounds of Formula (III) or (IV), or a pharmaceutically acceptable salt thereof, R5, for each occurrence, is independently —OCF3, —OCHF2, Cl, —CH2OCH3, —CH3, —CF3, —OCH3, —CH2CH3,
and the remaining variables are as described in the twentieth, twenty-first, twenty-second, twenty-third, or twenty-fourth embodiment.
In a twenty-sixth embodiment, the compound of the present disclosure is represented by Formula V:
or a pharmaceutically acceptable salt thereof; wherein the variables in Formula (V) are as defined in the first aspect or the first embodiment above.
In a twenty-seventh embodiment, the compound of the present disclosure is represented by Formula (VA) or (VB):
or a pharmaceutically acceptable salt thereof; wherein the variables in Formulas (VA) and (VB) are as defined in the twenty-sixth embodiment above.
In a twenty-eighth embodiment, for the compounds of Formula (V), (VA), or (VB), or a pharmaceutically acceptable salt thereof, R3 is selected from the group consisting of phenyl, pyrazolyl, isoxazoyl, and pyridinyl, each of which is optionally substituted with one to three R5; and the remaining variables are as described in the twenty-sixth or twenty-seventh embodiment.
In a twenty-ninth embodiment, for the compounds of Formula (V), (VA), or (VB), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
wherein each of the formula depicted above is optionally substituted with one to three R5; and the remaining variables are as described in the twenty-sixth, twenty-seventh, or twenty-eighth embodiment.
In a thirtieth embodiment, for the compounds of Formula (V), (VA), or (VB), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
and the remaining variables are as described in the twenty-sixth, twenty-seventh, twenty-eighth, or twenty-ninth embodiment.
In a thirty-first embodiment, for the compounds of Formula (V), (VA), or (VB), or a pharmaceutically acceptable salt thereof, R5, for each occurrence, is independently halo, —OR5a or C1-6alkyl; and the remaining variables are as described in the twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, or thirtieth embodiment.
In a thirty-second embodiment, for the compounds of Formula (V), (VA), or (VB), or a pharmaceutically acceptable salt thereof, R7 is H or OH; and the remaining variables are as described in the twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, or thirty-first embodiment.
In a thirty-third embodiment, for the compounds of Formula (V), (VA), or (VB), or a pharmaceutically acceptable salt thereof, R1 and R2 together with the nitrogen atom from which they are attached form a group represented by the following formula:
and the remaining variables are as described in the twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, or thirty-second embodiment.
In a thirty-fourth embodiment, the compound of the present disclosure is represented by Formula (VI) or (VII):
or a pharmaceutically acceptable salt thereof, wherein:
In a thirty-fifth embodiment, for the compounds of Formula (VI) or (VII), or a pharmaceutically acceptable salt thereof, Het is tetrahydropyranyl or oxetanyl; and the remaining variables are as defined in the thirty-fourth embodiment.
In a thirty-sixth embodiment, for the compounds of Formula (VI) or (VII), or a pharmaceutically acceptable salt thereof, R1 is:
or
each of which is optionally substituted with one or two R4; and the remaining variables are as defined in the thirty-fourth or thirty-fifth embodiment.
In a thirty-seventh embodiment, for the compounds of Formula (VI) or (VII), or a pharmaceutically acceptable salt thereof, R1 is —CH(CH3)CH2CH2OCH3 or CH2C(CH3)2OH, or R1 is represented by the following formula
and the remaining variables are as defined in the thirty-sixth embodiment.
In a thirty-eighth embodiment, for the compounds of Formula (VI) or (VII), or a pharmaceutically acceptable salt thereof, Ring A is
each of which is optionally substituted with one to two R4; and the remaining variables are as defined in the thirty-fourth embodiment.
In a thirty-ninth embodiment, for the compounds of Formula (VI) or (VII), or a pharmaceutically acceptable salt thereof, Ring A is
and the remaining variables are as defined in the thirty-eighth embodiment.
In a fortieth embodiment, for the compounds of Formula (VI) or (VII), or a pharmaceutically acceptable salt thereof, each R4 is independently —OH, —OCH3, —CH2OH, or —CH3; and the remaining variables are as described in the thirty-fourth, thirty-fifth, thirty-sixth, thirty-seventh, thirty-eighth, or thirty-ninth embodiment.
In a forty-first embodiment, for the compounds of Formula (VI) or (VII), or a pharmaceutically acceptable salt thereof, R5 is —OCHF2; and the remaining variables are as described in the thirty-fourth, thirty-fifth, thirty-sixth, thirty-seventh, thirty-eighth, thirty-ninth, or fortieth embodiment.
In a forty-second embodiment, the present disclosure provides a compound described herein (e.g., a compound of any one of Examples 1 to 77), or a pharmaceutically acceptable salt thereof.
In a forty-third embodiment, the present disclosure provides a compound selected from the group consisting of:
In a forty-fourth embodiment, the present disclosure provides a pharmaceutical composition comprising a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt thereof.
In a forty-fifth embodiment, the present disclosure provides a method of treating a disease or disorder mediated by EBP comprising administering to a subject an effective amount of a compound according to any one of embodiments one to forty-four, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the forty-fourth embodiment.
In a forty-sixth embodiment, the present disclosure provides a compound according to any one of embodiments one to forty-four, for use in the treatment of a disease or disorder mediated by EBP.
In a forty-seventh embodiment, the present disclosure provides the use of a compound according to any one of embodiments one to forty-four in the manufacture of a medicament for the treatment of a disease or disorder mediated by EBP.
The compounds and intermediates described herein may be isolated and used as the compound per se. Alternatively, when a moiety is present that is capable of forming a salt, the compound or intermediate may be isolated and used as its corresponding salt. As used herein, the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound described herein. “Salts” include in particular “pharmaceutical acceptable salts”. The term “pharmaceutically acceptable salts” refers to salts that retain the biological effectiveness and properties of the compounds described herein and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
Pharmaceutically acceptable acid addition salts can be formed with inorganic acids or organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfornate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, sulfate, sulfosalicylate, tartrate, tosylate and trifluoroacetate salts.
Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
The salts can be synthesized by conventional chemical methods from a compound containing a basic or acidic moiety. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca. Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in “Remington's Pharmaceutical Sciences”, 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
Isotopically-labeled compounds of Formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed. In one embodiment, the present disclosure provides deuterated compounds described herein or a pharmaceutically acceptable salt thereof.
Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, de-acetone, d6-DMSO.
It will be recognized by those skilled in the art that the compounds of the present invention may contain chiral centers and as such may exist in different stereoisomeric forms. As used herein, the term “an optical isomer” or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present disclosure. It is understood that a substituent may be attached at a chiral center of a carbon atom. Therefore, the disclosure includes enantiomers, diastereomers or racemates of the compound.
“Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term “racemic” or “rac” is used to designate a racemic mixture where appropriate. When designating the stereochemistry for the compounds of the present invention, a single stereoisomer with known relative and absolute configuration of the two chiral centers is designated using the conventional R—S system (e.g., (1S,2S)). “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R—S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (−) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Alternatively, the resolved compounds can be defined by the respective retention times for the corresponding enantiomers/diastereomers via chiral HPLC.
Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)— or (S)—.
Unless specified otherwise, the compounds of the present disclosure are meant to include all such possible stereoisomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)-stereoisomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques (e.g., separated on chiral SFC or HPLC chromatography columns, such as CHIRALPAK® and CHIRALCEL® available from DAICEL Corp. using the appropriate solvent or mixture of solvents to achieve good separation). If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
The compounds disclosed herein have EBP inhibitory activity. As used herein, “EBP inhibitory activity” refers to the ability of a compound or composition to induce a detectable decrease in EBP activity in vivo or in vitro (e.g., at least 10% decrease in EBP activity as measured by a given assay such as the bioassay described in the examples and known in the art).
In certain embodiments, the present disclosure provides a method of treating a disease or disorder responsive to inhibition of EBP activity (referred herein as “EBP mediated disease or disorder” or “disease or disorder mediated by EBP”) in a subject in need of the treatment. The method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a EBP mediated disorder or disease in a subject in need of the treatment.
In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of a EBP mediated disorder or disease in a subject in need of the treatment.
In certain embodiments, the EBP mediated disorder is colorectal cancer.
In certain embodiments, the present disclosure provides a method of treating an autoimmune disease in a subject in need of the treatment. The method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an autoimmune disease in a subject in need of the treatment.
In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease in a subject in need of the treatment.
In certain embodiments, the autoimmune disease is multiple sclerosis (MS). The compounds of the present disclosure can be used for treating all stages of MS, including relapsing multiple sclerosis (or relapsing form(s) of multiple sclerosis), relapsing-remitting multiple sclerosis, primary progress multiple sclerosis, secondary progressive multiple sclerosis and clinically isolated syndrome (hereinafter “CIS”).
Relapsing multiple sclerosis (or relapsing form(s) of multiple sclerosis) includes clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.
Relapsing-remitting multiple sclerosis is a stage of MS characterized by unpredictable relapses followed by periods of months to years of relative quiet (remission) with no new signs of disease activity. Deficits that occur during attacks may either resolve or leave problems, the latter in about 40% of attacks and being more common the longer a person has had the disease. This describes the initial course of 80% of individuals with multiple sclerosis.
Secondary progressive multiple sclerosis occurs in around 65% of those with initial relapsing-remitting multiple sclerosis, who eventually have progressive neurologic decline between acute attacks without any definite periods of remission. Occasional relapses and minor remissions may appear. The most common length of time between disease onset and conversion from relapsing-remitting to secondary progressive multiple sclerosis is 19 years.
Primary progressive multiple sclerosis is characterized by the same symptoms of secondary progressive multiple sclerosis, i.e., progressive neurologic decline between acute attacks without any definite periods of remission, without the prior relapsing-remitting stage.
CIS is a first episode of neurologic symptoms caused by inflammation and demyelination in the central nervous system. The episode, which by definition must last for at least 24 hours, is characteristic of multiple sclerosis but does not yet meet the criteria for a diagnosis of MS because people who experience a CIS may or may not go on to develop MS. When CIS is accompanied by lesions on a brain MRI (magnetic resonance imaging) that are similar to those seen in MS, the person has a high likelihood of a second episode of neurologic symptoms and diagnosis of relapsing-remitting MS. When CIS is not accompanied by MS-like lesions on a brain MRI, the person has a much lower likelihood of developing MS.
In certain embodiments, the present disclosure provides a method of promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment. The method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment.
In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment.
In certain embodiments, the myelin-related disease or disorder is selected from multiple sclerosis (MS), neuromyelitis optica (NMO), optic neuritis, pediatric leukodystrophies, neonatal white matter injury, age-related dementia, schizophrenia, progressive multifocal leukoencephalopathy (PML), encephalomyelitis (EPL), acute disseminated encephalomyelitis (ADEM), central pontine myelolysis (CPM), adrenoleukodystrophy, Alexander's disease, Pelizacus Merzbacher disease (PMD), Vanishing White Matter Disease, Wallerian Degeneration, transverse myelitis, amylotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, Parkinson's disease, spinal cord injury, traumatic brain injury, post radiation injury, neurologic complications of chemotherapy, stroke, acute ischemic optic neuropathy, vitamin E deficiency, isolated vitamin E deficiency syndrome, Bassen-Kornzweig syndrome, Marchiafava-Bignami syndrome, autism, metachromatic leukodystrophy, trigeminal neuralgia, acute disseminated encephalitis, chronic inflammatory demyelinating polyneuropathy, Guillian-Barre syndrome, Charcot-Marie-Tooth disease, Bell's palsy and radiation-induced demyelination, for example, neuromyelitis optica (NMO), optic neuritis, pediatric leukodystrophies, neonatal white matter injury, age-related dementia, and schizophrenia.
In certain embodiments, the present disclosure provides a method of treating cancer in a subject in need of the treatment. The method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer in a subject in need of the treatment.
In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to forty-third embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in treating cancer in a subject in need of the treatment.
In certain embodiments, the cancer is colorectal cancer.
In certain embodiments, the present disclosure relates to the aforementioned methods, wherein said subject is a mammal. In certain embodiments, the subject is a primate. In certain embodiments, the subject is a human.
As used herein, an “effective amount” and a “therapeutically effective amount” can used interchangeably. It means an amount effective for treating or lessening the severity of one or more of the diseases, disorders or conditions as recited herein. In some embodiments, the effective dose can be between 10 μg and 500 mg.
The compounds and compositions, according to the methods of the present disclosure, may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the diseases, disorders or conditions recited above.
In certain embodiments, the present disclosure relates to the aforementioned methods, wherein said compound is administered parenterally. In certain embodiments, the present disclosure relates to the aforementioned methods, wherein said compound is administered intramuscularly, intravenously, subcutaneously, orally, pulmonary, rectally, intrathecally, topically or intranasally. In certain embodiments, the present disclosure relates to the aforementioned methods, wherein said compound is administered systemically.
The compounds of the present invention can be used as a pharmaceutical composition (e.g., a compound of the present invention and at least one pharmaceutically acceptable carrier). As used herein, the term “pharmaceutically acceptable carrier” includes generally recognized as safe (GRAS) solvents, dispersion media, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, salts, preservatives, drug stabilizers, buffering agents (e.g., maleic acid, tartaric acid, lactic acid, citric acid, acetic acid, sodium bicarbonate, sodium phosphate, and the like), and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated. For purposes of this disclosure, solvates and hydrates are considered pharmaceutical compositions comprising a compound of the present invention and a solvent (i.e., solvate) or water (i.e., hydrate).
The formulations may be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (i.e., compound of the present invention or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent)) is dissolved in a suitable solvent in the presence of one or more of the excipients described above. The compound of the present invention is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to give the patient an elegant and easily handleable product.
The pharmaceutical composition (or formulation) for application may be packaged in a variety of ways depending upon the method used for administering the drug. Generally, an article for distribution includes a container having deposited therein the pharmaceutical formulation in an appropriate form. Suitable containers are well-known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like. The container may also include a tamper-proof assemblage to prevent indiscreet access to the contents of the package. In addition, the container has deposited thereon a label that describes the contents of the container. The label may also include appropriate warnings.
The pharmaceutical composition comprising a compound of the present disclosure is generally formulated for use as a parenteral or oral administration or alternatively suppositories.
For example, the pharmaceutical oral compositions of the present disclosure can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with
Tablets may be either film coated or enteric coated according to methods known in the art.
Suitable compositions for oral administration include a compound of the disclosure in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
The parenteral compositions (e.g., intravenous (IV) formulation) are aqueous isotonic solutions or suspensions. The parenteral compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. The compositions are generally prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
The compound of the present disclosure or pharmaceutical composition thereof for use in a subject (e.g., human) is typically administered orally or parenterally at a therapeutic dose of less than or equal to about 100 mg/kg, 75 mg/kg, 50 mg/kg. 25 mg/kg, 10 mg/kg, 7.5 mg/kg, 5.0 mg/kg. 3.0 mg/kg, 1.0 mg/kg, 0.5 mg/kg, 0.05 mg/kg or 0.01 mg/kg, but preferably not less than about 0.0001 mg/kg. When administered intravenously via infusion, the dosage may depend upon the infusion rate at which an IV formulation is administered. In general, the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, pharmacist, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. The dosage in vitro may range between about 10-3 molar and 10-9 molar concentrations.
As used herein, a “patient,” “subject” or “individual” are used interchangeably and refer to either a human or non-human animal. The term includes mammals such as humans. Typically, the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. Preferably, the subject is a human.
As used herein, the term “inhibit”. “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
As used herein, the term “treat”, “treating” or “treatment” of any disease, condition or disorder, refers to the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of the present invention to obtaining desired pharmacological and/or physiological effect. The effect can be therapeutic, which includes achieving, partially or substantially, one or more of the following results: partially or totally reducing the extent of the disease, condition or disorder; ameliorating or improving a clinical symptom, complications or indicator associated with the disease, condition or disorder; or delaying, inhibiting or decreasing the likelihood of the progression of the disease, condition or disorder; or eliminating the disease, condition or disorder. In certain embodiments, the effect can be to prevent the onset of the symptoms or complications of the disease, condition or disorder.
As used herein, the term “cancer” has the meaning normally accepted in the art. The term can broadly refer to abnormal cell growth.
As used herein, the term “autoimmune disease” has the meaning normally accepted the art. The term can broadly refer to a disease where the host's immune system targets or attacks normal or healthy tissue of the host.
As used herein, the term “myelination” has the meaning normally accepted in the art. The term can broadly mean the process by which myelin is produced.
As used herein, the term “myelin-related disease or disorder”, “demyelinating disorder”, or “demyelation disorder” has the meaning normally accepted in the art. These terms can broadly refer to diseases or disorders which involve damage to myelin.
As used herein, a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment (preferably, a human).
As used herein, the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general the term “optionally substituted” refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Specific substituents are described in the definitions and in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position.
As used herein, the term “alkyl” refers to a fully saturated branched or unbranched hydrocarbon moiety. The term “C1-4alkyl” refers to an alkyl having 1 to 4 carbon atoms. The terms “C1-3alkyl” and “C1-2alkyl” are to be construed accordingly. Representative examples of “C1-4alkyl” include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, and tert-butyl. Similarly, the alkyl portion (i.e., alkyl moiety) of an alkoxy have the same definition as above. When indicated as being “optionally substituted”, the alkane radical or alkyl moiety may be unsubstituted or substituted with one or more substituents (generally, one to three substituents except in the case of halogen substituents such as perchloro or perfluoroalkyls).
As used herein, the term “alkoxy” refers to a fully saturated branched or unbranched alkyl moiety attached through an oxygen bridge (i.e. a —O—C1-4 alkyl group wherein C1-4 alkyl is as defined herein). Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy and the like. Preferably, alkoxy groups have about 1-4 carbons, more preferably about 1-2 carbons. The term “C1-2 alkoxy” is to be construed accordingly.
As used herein, the term “C1-4 alkoxyC1-4 alkyl” refers to a C1-4 allkyl group as defined herein, wherein at least of the hydrogen atoms is replaced by an C1-4 alkoxy. The C1-4alkoxyC1-4 alkyl group is connected through the rest of the molecule described herein through the alkyl group.
The number of carbon atoms in a group is specified herein by the prefix “Cx-xx”, wherein x and xx are integers. For example, “C1-3 alkyl” is an alkyl group which has from 1 to 3 carbon atoms.
“Halogen” or “halo” may be fluorine, chlorine, bromine or iodine.
As used herein, the term “halo-substituted-C1-4alkyl” or “C1-4haloalkyl” refers to a C1-4 alkyl group as defined herein, wherein at least one of the hydrogen atoms is replaced by a halo atom. The C1-4haloalkyl group can be monohalo-C1-4alkyl, dihalo-C1-4alkyl or polyhalo-C1-4 alkyl including perhalo-C1-4alkyl. A monohalo-C1-4alkyl can have one iodo, bromo, chloro or fluoro within the alkyl group. Dihalo-C1-4alkyl and polyhalo-C1-4alkyl groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl. Typically the polyhalo-C1-4alkyl group contains up to 9, or 8, or 7, or 6, or 5, or 4, or 3, or 2 halo groups. Non-limiting examples of C1-4haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. A perhalo-C1-4alkyl group refers to a C1-4alkyl group having all hydrogen atoms replaced with halo atoms.
The term “aryl” refers to an aromatic carbocyclic single ring or two fused ring system containing 6 to 10 carbon atoms. Examples include phenyl and naphthyl.
The term “heteroaryl” refers to a 5- to 12-membered aromatic radical containing 1-4 heteroatoms selected from N, O, and S. In some instances, nitrogen atoms in a heteroaryl may be quaternized. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”. A heteroaryl group may be mono- or bi-cyclic. Monocyclic heteroaryl includes, for example, pyrazolyl, imidazolyl, oxazolyl, pyridinyl, furanyl, oxadiazolyl, thiophenyl, and the like. Bi-cyclic heteroaryls include groups in which a monocyclic heteroaryl ring is fused to one or more aryl or heteroaryl rings. Non-limiting examples include pyrazolopyridinyl, pyrazolopyridinyl, benzotriazolyl, imidazopyridinyl, and indoyl.
The term “carbocyclic ring” or “carbocyclyl” refers to a 4- to 12-membered saturated or partially unsaturated hydrocarbon ring and may exist as a single ring, bicyclic ring (including fused, spiral or bridged carbocyclic rings) or a spiral ring. Bi-cyclic carbocyclyl groups include, e.g., unsaturated carbocyclic radicals fused to another unsaturated carbocyclic radical, cycloalkyl, or aryl, such as, for example, 2,3-dihydroindenyl, decahydronaphthalenyl, and 1,2,3,4-tetrahydronaphthalenyl. Unless specified otherwise, the carbocyclic ring generally contains 4- to 10-ring members.
The term “C3-6 cycloalkyl” refers to a carbocyclic ring which is fully saturated (e.g., cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl).
The term “heterocycle” or “heterocyclyl” refers to a 4- to 12-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S. A heterocyclyl group may be mono- or bicyclic (e.g., a bridged, fused, or spiro bicyclic ring). Examples of monocyclic saturated or partially unsaturated heterocyclic radicals include, without limitation, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, and piperdinyl. Bi-cyclic heterocyclyl groups include, e.g., unsaturated heterocyclic radicals fused to another unsaturated heterocyclic radical, cycloalkyl, aryl, or heteroaryl ring, such as, for example, tetrahydro-3H-[1,2,3]triazolo[4,5-c]pyridinyl, 2-oxa-6-azaspiro[3.3]heptanyl, 5-oxabicyclo[2.1.1]hexanyl and 9-azabicyclo[3.3.1]nonanyl. In some embodiments, the heterocyclyl group is a 4 to 6 membered monocyclic heterocyclyl group. In some embodiments, the heterocyclyl group is a 4 to 6 membered monocyclic saturated heterocyclyl group. In some embodiments, the heterocyclyl group is a 8 to 10 membered bicyclic heterocyclyl group. In some embodiments, the heterocyclyl group is a 8 to 10 membered bicyclic saturated heterocyclyl group.
As used herein the term “spiral” ring means a two-ring system wherein both rings share one common atom. Examples of spiral rings include, 2-oxa-6-azaspiro[3.3]heptanyl and the like.
The term “fused” ring refers to two ring systems share two adjacent ring atoms. Fused heterocycles have at least one the ring systems contain a ring atom that is a heteroatom selected from O, N and S (e.g., 3-oxabicyclo[3.1.0]hexane).
As used herein the term “bridged” refers to a 5 to 10 membered cyclic moiety connected at two non-adjacent ring atoms (e.g. 5-oxabicyclo[2.1.1]hexane).
The phrase “pharmaceutically acceptable” indicates that the substance, composition or dosage form must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
Unless specified otherwise, the term “compounds of the present disclosure” refers to compounds of Formula (I), as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, isotopically labeled compounds (including deuterium substitutions). When a moiety is present that is capable of forming a salt, then salts are included as well, in particular pharmaceutically acceptable salts.
As used herein, the term “a,” “an,” “the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed.
It is also possible that the intermediates and compounds of the present invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. The term “tautomer” or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. A specific example of a proton tautomer is the imidazole moiety where the proton may migrate between the two ring nitrogens. Valence tautomers include interconversions by reorganization of some of the bonding electrons.
In one embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in free form. In another embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in salt form. In another embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in acid addition salt form. In a further embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in pharmaceutically acceptable salt form. In yet a further embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in pharmaceutically acceptable acid addition salt form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in free form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in salt form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in acid addition salt form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in pharmaceutically acceptable salt form. In still another embodiment, the present disclosure relates to any one of the compounds of the Examples in pharmaceutically acceptable acid addition salt form.
Compounds of the present disclosure may be synthesized by synthetic routes that include processes analogous to those well-known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources such as Sigma-Aldrich or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19, Wiley, New York (1967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).
For illustrative purposes, the reaction schemes depicted below provide potential routes for synthesizing the compounds of the present disclosure as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section below. Although specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions.
A mixture of tert-butyl (1R,3r,5S)-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (15 g, 66.3 mmol), 1,5-dibromo-3-methylpentane (17.79 g, 72.9 mmol) and DIPEA (25.4 mL, 145.8 mmol,) in IPA (250 mL) was heated under reflux for 72 h. The solvent was removed in vacuo and the residue diluted with water (100 mL) and extracted with EtOAc (3×50 mL). The combined organics were dried (Na2SO4), filtered, and evaporated to dryness to give tert-butyl (1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate as a yellow oil (19 g, crude; purity 90%) which was used without further purification in the next step. LCMS m/z=309.2 [M+H]+.
To a solution of tert-butyl (1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (18.8 g, 61.0 mmol) in DCM (100 mL) was added TFA (14 mL, 183 mmol) and the resulting solution stirred at room temperature for 48 h. The reaction mixture was evaporated to dryness in vacuo and the residue diluted with sat. aq. NaHCO3 and extracted with EtOAc (3×50 mL). The combined organics were washed with water (50 mL), brine (50 mL), dried (Na2SO4), filtered, and evaporated to dryness in vacuo to afford (1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane as a yellow solid (11.2 g, 88%) which was used without further purification. LCMS m/z=209.2 [M+H]+.
DIPEA (340 μL, 1.9 mmol) was added to a solution of tert-butyl (1R,3s,5S)-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (200 mg, 0.9 mmol) and 1,5-dibromo-3-methyl-pentane (237 mg, 1.0 mmol) in IPA (10 mL) and the reaction mixture was heated under reflux for 72 h. The reaction mixture was evaporated to dryness in vacuo. The residue was diluted with water (10 mL) and extracted with EtOAc (3×10 mL). The combined organics were dried (Na2SO4), filtered, and evaporated to dryness to afford tert-butyl (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate as a yellow oil (200 mg, crude) which was used without further purification. LCMS m/z=309.2 [M+H]+.
TFA (13.8 mL, 180 mmol) was added to a solution of tert-butyl (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (18.5 g, 60 mmol) in DCM (100 mL) and the resulting solution stirred at room temperature for 48 h. The reaction mixture was concentrated under reduced pressure and the residue was taken up in sat. aq. NaHCO3 and extracted with EtOAc (3×50 mL). The combined organics were washed with water (50 mL), brine (50 mL), dried (Na2SO4), filtered, and evaporated to dryness in vacuo. The resulting yellow oil was crystallized from DCM/Hexanes (100/300 mL) and the solids collected by cold filtration and air-dried to afford (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane as a yellow solid (6.3 g, 50%). LCMS m/z=209.2 [M+H]+.
To a solution of tert-butyl ((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl) carbamate (1.13 g, 5.0 mmol) and DIPEA (1.74 mL, 10.0 mmol) in DCM (25 mL) was added 4-(difluoromethoxy) benzenesulfonyl chloride (1.21 g, 5 mmol) and the mixture stirred at room temperature overnight. The organic phase was washed with sat. aq. NaHCO3 and water, dried (MgSO4), filtered, and evaporated to dryness in vacuo. The residue was purified by column chromatography (24 g SiO2, 10-40% EtOAc in heptane) to give tert-butyl ((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)-sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl) carbamate as a white solid (1.42 g, 66%). LCMS m/z=433.1 [M+H]+
TFA (200 μL, 2.71 mmol) was added dropwise at room temperature to a solution of tert-butyl ((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl) carbamate (468 mg, 1.1 mmol) in HFIP (3 mL) and the resulting mixture stirred at room temperature overnight. The reaction mixture was evaporated to dryness in vacuo and the co-evaporated with MeCN (×3) to afford (1R,3r,5S)-8-((4-resulting residue (difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine as a white solid (543 mg, 100%). LCMS m/z=333.1 [M+H]+.
To a solution of tert-butyl ((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)carbamate (1.13 g, 5.0 mmol) and DIPEA (1.74 mL, 10.0 mmol) in DCM (25 mL) was added 4-(difluoromethoxy) benzenesulfonyl chloride (1.21 g, 5 mmol) and the mixture stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with sat. aq. NaHCO3 and water, dried (MgSO4), filtered, and evaporated to dryness in vacuo. The resulting residue was triturated with MeCN to give tert-butyl ((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)-sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl) carbamate as a white solid (1.88 g, 87%). LCMS m/z=433.1 [M+H]+.
TFA (220 μL, 2.9 mmol) was added dropwise at room temperature to a solution of tert-butyl ((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl) carbamate (468 mg, 1.1 mmol) in HFIP (3 mL), then the resulting mixture was stirred at room temperature for 3 h. The reaction mixture was evaporated to dryness in vacuo and the resulting residue was co-evaporated with MeCN (×3) to afford (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine trifluoroacetate as a white solid (521 mg, 100%). LCMS m/z=333.1 [M+H]+.
To a mixture of (1S,5R)-8-azabicyclo[3.2.1]octan-3-one hydrochloride (666 mg, 4.1 mmol) and 4-(difluoromethoxy) benzenesulfonyl chloride (656 μL, 4.1 mmol) in DCM (8 mL) was added DIPEA (2.15 mL, 12.4 mmol). The reaction mixture was stirred at room temperature for 6 h. The organic phase was washed with sat. aq. NaHCO3, water, dried (MgSO4), filtered, and evaporated to dryness. The resulting residue was purified by column chromatography (80 g SiO2, 10-40% EtOAc in heptane) to afford 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one as a white solid (1.85 g, 79%). LCMS m/z=332.0 [M+H]+.
DIPEA (92 μL, 0.5 mmol) was added dropwise to a solution of 8-azabicyclo[3.2.1]octan-3-one hydrochloride (177 mg, 1.1 mmol) and 2-methyl-6-(trifluoromethyl)pyridine-3-sulfonyl chloride (263 mg, 1.0 mmol) in DCM (5 mL) and the resulting mixture stirred at room temperature overnight.
The reaction mixture was diluted with EtOAc and the organic phase washed with sat. aq. NaHCO3 and water, dried (MgSO4), filtered, and evaporated to dryness in vacuo. The residue was purified by column chromatography (24 g SiO2, 20-50% EtOAc in heptane) to afford 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one as a colorless oil (322 mg, 91%). LCMS m/z=349.1 [M+H]+.
NaBH(OAc)3 (36.54 g, 172 mmol) was added portion wise at room temperature to a solution of tert-butyl (1R,3s,5S)-3-formyl-8-azabicyclo[3.2.1]octane-8-carboxylate (27.5 g, 115 mmol) and morpholine (10.52 g, 121 mmol) in DCE (300 mL) and the resulting mixture stirred overnight at rt. MeOH (150 mL) was added, and the reaction mixture was evaporated to dryness. The residue was quenched with 15% potassium carbonate solution, extracted with EtOAc (2×250 mL). The combined organics were washed with water, dried (Na2SO4), filtered and evaporated in vacuo to afford tert-butyl (1R,3s,5S)-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (27.4 g, 77%).
tert-Butyl (1R,3s,5S)-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (27.4 g, 88.3 mmol) was dissolved in HCl solution in MeOH (150 mL) and stirred overnight. The solvent was evaporated and THF (150 mL) added to the residue. The precipitate was collected by filtration and washed with THF (2×75 mL) and dried to afford 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine dihydrochloride as a white solid (17.6 g, 70%). 1H NMR (500 MHZ, DMSO-d6) δ (ppm): 3.89 (dd, J=14.4, 10.3 Hz, 6H), 3.45 (d, J=12.6 Hz, 2H), 2.99 (q, J=12.6, 11.8 Hz, 2H), 2.91 (t, J=6.0 Hz, 2H), 2.33 (dt, J=11.8, 6.2 Hz, 1H), 1.96-1.83 (m, 6H), 1.63 (t, J=12.6 Hz, 2H).
4-(((1R,3r,5S)-8-Azabicyclo[3.2.1]octan-3-yl)methyl)morpholine was prepared from tert-butyl (1R,3r,5S)-3-formyl-8-azabicyclo[3.2.1]octane-8-carboxylate and morpholine using an analogous 2-step method as described for Intermediate 7. 1H NMR (400 MHZ, DMSO-d6) δ (ppm): 4.02-3.82 (m, 6H), 3.47 (d, J=12.4 Hz, 2H), 3.08-2.85 (m, 4H), 2.36 (dd, J=11.4, 5.9 Hz, 1H), 2.00-1.82 (m, 6H), 1.71-1.58 (m, 2H). LCMS m/z=211.2 [M+H]+.
tert-Butyl (1R,3s,5S)-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (2.5 g, 11 mmol) was dissolved in dry DCM (50 mL) and trimethylamine (1.11 g, 11 mmol) was added. The mixture was cooled to 0° C. and trifluoroacetic anhydride (2.31 g, 11 mmol) was added dropwise. The reaction mixture was warmed up to 20° C. and stirred for 18 h. The resulting mixture was washed with water (100 mL) and an aqueous NaHSO4 solution (50 mL), dried over Na2SO4, filtered, and concentrated in vacuo to obtain tert-butyl (1R,3s,5S)-3-(2,2,2-trifluoroacetamido)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.38 g, 95% yield) as a yellow oil.
tert-Butyl (1R,3s,5S)-3-(2,2,2-trifluoroacetamido)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.38 g, 10.5 mmol) was dissolved in 4 N HCl/dioxane solution and the reaction mixture was stirred for 4 h at 20° C. The volatiles were removed in vacuo and the residue was washed with diethyl ether (50 mL) and dried in vacuo to obtain N-((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)-2,2,2-trifluoroacetamide (2.64 g, 97% yield) as a white solid.
N-((1R,3s,5S)-8-Azabicyclo[3.2.1]octan-3-yl)-2,2,2-trifluoroacetamide (1 g, 4.5 mmol) was suspended in dry DCM (50 mL) and the mixture was cooled to 0° C. After that 2-methyl-6-(trifluoromethyl)pyridine-3-sulfonyl chloride (1 g, 3.9 mmol) was added in one portion followed by slow addition of DIPEA (1 g, 7.8 mmol). The reaction mixture was warmed up to 20° C. and stirred for 18 h at 20° C. The resulting mixture was washed with water (100 mL) and an aqueous NaHCO3 solution (100 mL), dried over Na2SO4, and filtered through silica gel (100 mL) which was washed with MTBE (100 mL). Volatiles were removed in vacuo to obtain 2,2,2-trifluoro-N-((1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)acetamide as a viscous yellow oil (1.7 g, 97% yield).
2,2,2-Trifluoro-N-((1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)acetamide (1.7 g, 3.8 mmol) was dissolved in methanol (50 mL) and a solution of NaOH (0.76 g, 19 mmol) in water (10 mL) was added. The resulting mixture was stirred for 72 h at 20° C. Volatiles were removed in vacuo and the residue was diluted with an aqueous NaHSO4 solution (250 mL) and washed with MTBE (100 mL). The aqueous layer was basified with NaOH and extracted with MTBE (3×100 mL). Combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to obtain (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (1.3 g, 3.7 mmol, 98% yield) as a yellow oil. 1H NMR (500 MHZ, Chloroform-d) δ 8.44 (d, J=8.0 Hz, 1H), 7.65 (d, J=8.1 Hz, 1H), 4.28-4.14 (m, 2H), 3.11 (tt, J=11.6, 5.9 Hz, 1H), 2.94 (d, J=1.7 Hz, 3H), 2.15-1.98 (m, 2H), 1.90 (ddd, J=13.5, 5.5, 2.8 Hz, 2H), 1.81-1.70 (m, 2H), 1.57-1.30 (m, 4H).
The title compounds were prepared using a single step library protocol as described below. Each reaction was carried out on an approximate 50 mg target product scale.
The appropriate sulfonyl chloride (RSO2Cl, 1.1 equiv.) was added to a solution of (1R,3r,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (Intermediate 1, 1.0 equiv.) and DIPEA (2.5 equiv.) in dry MeCN (1.2 mL) and the resulting mixture stirred at room temperature for 16 h. The solvent was evaporated in vacuo and the residue dissolved in DMSO (800 μL) and purified by prep-HPLC (YMC Actus Trial C18 20×100 mm, 5 μm; MeOH/water+0.1% NH4OH) to afford the title compound. Gradient optimized for each compound.
The title compounds were prepared using a single step library protocol on an approximately 50 mg target product scale as described below.
The appropriate sulfonyl chloride (RSO2Cl) (1.1 equiv.) was added to the solution of (1R,3s,5S)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (Intermediate 2, 1.0 equiv.) and DIPEA (2.5 equiv.) in dry MeCN (1.2 mL) and the reaction mixture stirred at room temperature for 16 h. The solvent was evaporated to dryness in vacuo and the residue was dissolved in DMSO (800 μL) and purified by prep-HPLC to afford the title compound. Solvent gradient optimized for each compound.
1H NMR (500 MHz, DMSO-d6) δ (ppm): 10.41 (s, 1H),
1H NMR (400 MHz, acetonitrile-d3) δ (ppm): 7.51 (s,
1H NMR (500 MHz, DMSO-d6) δ (ppm): 8.98 − 8.80 (m,
1H NMR: (500 MHz, METHANOL-d4) δ =
General procedure for reductive amination of primary (RNH2) and secondary amines (R1R2NH)
The title compounds were prepared using a single step reductive amination protocol on an approximately 50 mg target product scale using either the Primary Amine or Secondary Amine protocols outlined below.
Primary Amine Protocol: The appropriate primary amine (RNH2, 1.3 equiv.), 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5, 1.0 equiv.) and NaBH(OAc)3 (4.0 equiv.) were dissolved in CHCl3 (1.2 mL) and AcOH (1.2 equiv.), then the mixture stirred at room temperature for 24 h. The reaction mixture was concentrated under reduced pressure, and the residue was taken up in 5% ammonia in MeOH (1.2 mL) and stirred at room temperature for 0.5 h. The mixture was concentrated under reduced pressure and the residue was dissolved in the DMSO (0.7 mL) and purified by prep-HPLC (YMC Actus Triart C18 20×100 mm, 5 μm; gradient mixture water-MeOH+0.1% NH4OH) to afford the title compound. In the case of using primary amines as HCl salts, an additional 1.4 equiv. DIPEA per each equivalent of acid was added to the reaction mixture. The molar ratios of the starting materials and overall reaction conditions were unchanged.
Secondary Amine Protocol: NaBH(OAc)3 (3.0 equiv.) was added to a solution of 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5, 1.0 equiv.) and the appropriate secondary amine (R1R2NH, 1.1 equiv.) in 1,2-dichloroethane (1 mL) and the resulting solution stirred at 50° C. for 16 h. The reaction mixture was concentrated under reduced pressure, and the residue was taken up in sat. aq. NaHCO3 and extracted with EtOAc (2×10 mL). The combined organics were washed with water (10 mL), brine (10 mL), dried (Na2SO4) and evaporated to dryness in vacuo. The residue was dissolved in DMSO (500 μL) and purified by prep-HPLC (YMC Actus Triart C18 20×100 mm, 5 μm; gradient mixture water-MeOH+0.1% NH4OH) to afford the title compounds.
1H NMR (400 MHz, CD3OD) δ (ppm): 7.97 − 7.89 (m, 2H),
1H NMR (400 MHz, DMSO-d6 + CCl4) δ (ppm): 7.93 − 7.78
To a mixture of 1,6-dioxaspiro[2.5]octane (11 mg, 0.1 mmol) and (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3, 41 mg, 0.1 mmol) in EtOH (2 mL) was added DIPEA (36 μL, 0.2 mmol), and the mixture stirred at 60° C. overnight. Additional 1,6-dioxaspiro[2.5]octane was added then continued heating at 60° C. overnight. The reaction mixture was evaporated to dryness and dissolved in DMSO and purified by prep-HPLC (Waters Xselect CSH Prep C18 30×100 mm, 5 μm; 5-55% MeCN in water (+NH4OH)) to afford 4-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)tetrahydro-2H-pyran-4-ol as a white solid (16 mg, 44%). LCMS m/z=447.1 [M+H]+, tR=0.56 min.
The title compound was prepared as a white solid (7.1 mg, 18%) from 1,6-dioxaspiro[2.5]octane and (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 4) using an analogous procedure to that described for Example 17 to afford the desired compound (16 mg, 44%). LCMS m/z=446.8 [M+H]+, tR=0.55 min.
Acetic acid (34 μL, 0.6 mmol) was added to a mixture of tetrahydropyran-4-ylmethanamine (28 mg. 0.2 mmol) and 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5, 66 mg. 0.2 mmol) in DCM (3 mL). NaBH(OAc)3 (170 mg. 0.8 mmol) was added in one portion to the above solution, then the mixture was stirred at room temperature overnight. The reaction was quenched with sat. aq. NH4Cl and stirred at room temperature for 5 min. The mixture was diluted with DCM and sat. aq. NaHCO3 then stirred for another 5 min. The organic phase was washed with water and evaporated to dryness in vacuo. The residue was dissolved in DMSO purified by prep-HPLC (Waters Xselect CSH Prep C18 30×100 mm, 5 μm; 5-70% MeCN in water (+NH4OH)) to afford 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine as a white solid (24 mg, 28%). LCMS m/z=431.2 [M+H]+, tR=0.58 min.
8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and 4-methylpiperidine using an analogous method to that described for Example 19. Purification by preparative HPLC (Waters SunFire C18 19*100 5 mkm column; gradient mixture water-ACN-FA 0.1% as a mobile phase) afforded the title compound (91 mg, 30%). LCMS m/z=415.2 [M+H]+.
8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(4-methylpiperidin-1-yl)-8-azabicyclo[3.2.1]octane (60 mg) was separated into its stereoisomers using CHIRALPAK AD-H 4.6×150 mm, 5 μm, 30% MeOH w/0.1% DEA in CO2 (flow rate: 100 mL/min, ABPR 120 bar, MBPR 40 psi, column temp 40° C.) to yield two stereoisomers:
6-((1R,5S)-8-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)-2-oxa-6-azaspiro[3.3]heptane was prepared from 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 6) and 2-oxa-6-azaspiro[3.3]heptane using an analogous method to that described for Example 19. Purification by column chromatography (24 g SiO2, 20-50-100% EtOAc/EtOH (3/1) in heptane) afforded:
(1R,5S)-8-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 6) and tetrahydropyran-4-ylmethanamine using an analogous method to that described for Example 19. Purification by column chromatography (24 g SiO2, 20-100% EtOAc/EtOH (3/1) in heptane) afforded:
(1R,5S)-8-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 6) and (3-methyloxetan-3-yl) methanamine using an analogous method to that described for Example 19. Purification by column chromatography (24 g SiO2, 20-100% EtOAc/EtOH (3/1) in heptane) afforded:
To a mixture of (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 4, 45 mg. 0.1 mmol) and 3-methyloxetane-3-carbaldehyde (14 mg. 0.1 mmol) in DCM (3 mL) was added acetic acid (17 μL, 0.3 mmol). NaBH(OAc)3 (85 mg, 0.4 mmol) was added in one portion and the mixture stirred at room temperature overnight. The reaction was quenched with sat. aq. NH4Cl, and the mixture was stirred at room temperature for 5 min. Additional DCM and sat. NaHCO3were added, and the reaction mixture stirred for another 5 min. The organic phase was washed with water then evaporated to dryness in vacuo. The residue was dissolved in DMSO purified by prep-HPLC (Waters Xselect CSH Prep C18 30×100 mm, 5 μm; 5-55% MeCN in water (+NH4OH)) to afford (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((3-methyloxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine as a white solid (27 mg, 64%). LCMS m/z=417.1 [M+H]+, tR=0.57 min.
Acetic acid (21 μL, 0.4 mmol) and NaBH(OAc)3 (105 mg, 0.5 mmol) were added to a mixture of (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine trifluoroacetate (Intermediate 4, 55 mg, 0.1 mmol) and tetrahydropyran-4-carbaldehyde (15.5 mg, 0.1 mmol) in DCM (2 mL), and the mixture stirred at room temperature for 2 h. The reaction was quenched with sat. aq. NaHCO3, diluted with DCM and stirred for 5 min. The organic phase was washed with water, dried (MgSO4) and evaporated to dryness in vacuo. The residue was purified by column chromatography (12 g SiO2, EtOAc/EtOH 3/1) to afford (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine as a white solid (32 mg, 60%). 1H NMR (400 MHZ, CD3OD) δ (ppm): 8.01-7.89 (m, 2H), 7.32 (d, J=8.5 Hz, 2H), 7.23-6.78 (m, 1H), 4.29 (br s, 2H), 3.94 (br dd, J=11.4, 4.1 Hz, 2H), 3.42 (t, J=11.7 Hz, 2H), 2.91 (dt, J=11.2, 5.6 Hz, 1H), 2.46 (d, J=6.5 Hz, 2H), 2.09-1.94 (m, 2H), 1.79-1.45 (m, 9H), 1.38-1.15 (m, 2H). LCMS m/z=431.2 [M+H]+.
DIPEA (70 μL, 0.4 mmol) was added to a mixture of 1-methyl-2-oxabicyclo[2.1.1]hexan-4-amine HCl salt (36 mg, 0.2 mmol) and 8-[4-(difluoromethoxy)phenyl]sulfonyl-8-azabicyclo[3.2.1]octan-3-one (66 mg, 0.2 mmol) in DCM (3 mL). NaBH(OAc)3 (170 mg, 0.8 mmol) was added in one portion to the above solution, and the mixture was stirred at room temperature overnight. Additional NaBH(OAc)3 (85 mg, 0.4 mmol) was added and stirring continued at room temperature overnight. The reaction was quenched with sat. aq. NH4Cl and stirred at room temperature for 5 min. The reaction mixture was diluted with DCM and sat. aq. NaHCO3 and stirred for another 5 min. The organic phase was washed with water and concentrated. The residue was dissolved in DMSO and purified by prep-HPLC (Waters Xselect CSH Prep C18 30×100 mm, 5 μm; 5-70% MeCN in water (+NH4OH)) to afford 8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-8-azabicyclo[3.2.1]octan-3-amine as a white solid (20 mg, 23%). LCMS m/z=429.1 [M+H]+, tR=0.60 min.
(1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-amine was prepared as a white solid (23.8 mg, 59%) from (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 4) and oxetane-3-carbaldehyde using an analogous method to that described for Example 28 to afford the desired compound (31 mg, 76%). LCMS m/z=402.9 [M+H]+, tR=0.56 min.
(1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine (35 mg, 75%) was prepared from (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3) and tetrahydro-2H-pyran-4-carbaldehyde using an analogous method to that described for Example 28. LCMS m/z=431.2 [M+H]+, tR=0.59 min.
Trimethylsulfoxonium iodide (2.93 g, 13.32 mmol) was added to a suspension of NaH (533 mg, 13.3 mmol, 60% purity) in DMSO (5 mL) and stirred under N2 at 25° C. for 1 h before a solution of tert-butyl (1R,5S)-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (2 g, 8.9 mmol) in DMSO (5 mL) was added. After consumption of starting material, water (20 mL) was added, and the resulting mixture extracted with DCM (3×50 mL). The combined organics were washed with brine (20 mL), dried (Na2SO4), filtered, and evaporated to dryness in vacuo. The residue was purified by column chromatography (SiO2, 0-17% EtOAc/PE) to give compound tert-butyl (1R,3r,5S)-8-azaspiro[bicyclo[3.2.1]octane-3,2′-oxirane]-8-carboxylate as a colorless oil (1.5 g, 71%). LCMS m/z=183.9 [M-t-Bu+H]+.
Morpholine (145 μL, 1.7 mmol) was added to a solution of tert-butyl (1R,3r,5S)-8-azaspiro [bicyclo[3.2.1]octane-3,2′-oxirane]-8-carboxylate (200 mg, 0.8 mmol) in EtOH (5 mL) and the resulting mixture stirred under N2 at 25° C. for 1 h and then at 100° C. for an additional 15 h. The reaction mixture was evaporated to dryness in vacuo and the residue purified by column chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, 30-90% EtOAc/PE) to afford tert-butyl (1R,3r,5S)-3-hydroxy-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate as a colorless oil (130 mg, 48%). LCMS m/z=327.1 [M+H]+.
TFA (2.98 g, 26.1 mmol, 2.00 mL) was added to a solution of compound tert-butyl (1R,3r,5S)-3-hydroxy-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (130 mg, 0.4 mmol) in DCM (10 mL) and the mixture was stirred under N2 at 25° C. for 0.5 h. The reaction mixture was evaporated to dryness in vacuo to give (1R,3r,5S)-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octan-3-ol trifluoroacetate as a yellow oil (150 mg, crude) which was used without further purification. 1H NMR (400 MHZ, CD3OD) δ (ppm): 3.58 (br s, 2H), 3.18 (s, 4H), 2.54-2.46 (m, 4H), 2.16-2.13 (m, 6H), 2.11-2.06 (m, 4H).
4-(Difluoromethoxy) benzenesulfonyl chloride (100 mg, 0.4 mmol) was added to a solution of (1R,3r,5S)-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octan-3-ol trifluoroacetate (100 mg, 0.4 mmol) and DIPEA (340 μL, 1.9 mmol) in DCM (20 mL) at 0° C. and the resulting mixture stirred under N2 at 25° C. for 1 h. Water (10 mL) was added to the reaction mixture and extracted with DCM (3×30 mL). The combined organics were washed with brine (20 mL), dried (Na2SO4), filtered, and evaporated to dryness in vacuo. The residue was purified by prep-HPLC (Welch Xtimate C18 25×150 mm, 5 mm; 50-80% MeCN/water (10 mM NH4HCO3)) to give (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octan-3-ol as a white solid (80 mg, 49%). 1H NMR (400 MHZ, CD3OD) δ (ppm): 7.92 (d, J=8.8 Hz, 2H), 7.29 (d, J=8.4 Hz, 2H), 7.00 (t, J=73.2 Hz, 1H), 4.21 (br s, 2H), 3.67-3.63 (m, 4H), 2.55-2.52 (m, 4H), 2.14-2.08 (m, 4H), 1.89-1.84 (m, 2H), 1.76-1.72 (m, 2H), 1.42-1.40 (m, 2H). LCMS m/z (ESI): 433.1 [M+H]+.
Methyl(triphenyl)phosphonium bromide (55.50 g, 155.4 mmol) was added to a solution of potassium tert-butoxide (1 M, 155.4 mL) in THF (40 mL) under N2 at 0° C. and the resulting mixture stirred at 0° C. for 15 min followed by heating at 80° C. for 1 h. The reaction mixture was cooled to room temperature and a solution of tert-butyl (1S,5R)-3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (7 g, 31.1 mmol) in THF (60 mL) was added dropwise and stirred at 25° C. for 15 h. The reaction mixture was diluted with acetone (30 mL) and the resulting solids removed by filtration. The filtrate was diluted with water (80 mL) and extracted with EtOAc (3×100 mL). The combined organics were washed with brine (50 mL), dried (Na2SO4), filtered, and evaporated to dryness in vacuo. The residue was purified by column chromatography (ISCO®; 330 g SepaFlash® Silica Flash Column, Eluent of 5-20% EtOAc/PE gradient) to give tert-butyl (1R,5S)-3-methylene-8-azabicyclo[3.2.1]octane-8-carboxylate as a colorless oil (5 g, 72%). LCMS m/z (ESI): 168.1 [M-t-Bu+H]+.
3-Chlorobenzenecarboperoxoic acid (22.7 g, 112 mmol, 85% purity) was added to a solution of tert-butyl (1R,5S)-3-methylene-8-azabicyclo[3.2.1]octane-8-carboxylate (10 g, 44.8 mmol) in DCM (100 mL) at 0° C. The reaction mixture was stirred at 25° C. for 24 h before additional 3-chlorobenzenecarboperoxoic acid (9.09 g, 44.8 mmol, 85% purity) was added and stirring continued at 25° C. for another 24 h. The resulting solid were removed by filtration and sat. aq. NaHCO3 (50 mL) was added to the filtrate. The aqueous phase was extracted with DCM (3×80 mL). The combined organics were washed with sat. aq. Na2SO3 (50 mL), brine (20 mL), dried (Na2SO4), filtered, and evaporated to dryness in vacuo. The residue was purified by column chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, 15-35% EtOAc/PE) to give:
A mixture of tert-butyl (1R,3s,5S)-8-azaspiro [bicyclo[3.2.1]octane-3,2′-oxirane]-8-carboxylate (1 g, 4.2 mmol) and ammonia (7 M, 13.3 mL) in water was heated in an autoclave at 60° C. for 96 h. The mixture was concentrated under reduced pressure to give tert-butyl (1R,3s,5S)-3-(aminomethyl)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate as a yellow oil (1 g, crude) which was used without further purification. 1H NMR (400 MHZ, CD3OD) δ (ppm): 4.35-4.21 (m, 2H), 2.76 (s, 2H), 2.10-1.93 (m, 4H), 1.81 (br d, J=7.2 Hz, 2H), 1.47 (s, 9H), 1.29 (br d, J=12.4 Hz, 2H). LCMS m/z (ESI): 201.1 [M-tBu+H]+.
Oxybis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate) (2.91 g, 7.0 mmol) was added to a mixture of tert-butyl (1R,3s,5S)-3-(aminomethyl)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate (1.2 g, 4.7 mmol) and K2CO3 (1.94 g, 14.0 mmol) in MeCN (30 mL) under N2 and the mixture stirred at 80° C. for 15 h. The solids were removed by filtration and the filtrate concentrated under reduced pressure. The residue was purified by column chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column; 0-10% MeOH/DCM) followed by prep-HPLC (YMC-Actus Triart C18 150×30 mm, 5 μm, 4-60% MeCN/water (0.05% NH4OH)) to afford tert-butyl (1R,3s,5S)-3-hydroxy-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate as a white solid (22 mg, 1.44%). 1H NMR (400 MHZ, DMSO-d6) δ (ppm): 4.27 (s, 1H), 4.00 (br s, 2H), 3.56 (br t, J=4.0 Hz, 4H), 3.44-3.38 (m, 4H), 2.36 (s, 2H), 1.96 (br s, 2H), 1.80 (br s, 2H), 1.71-1.54 (m, 4H), 1.41 (s, 9H). LCMS m/z (ESI): 327.2 [M+H]+.
HCl/dioxane (4 M, 2 mL) was added to a solution of tert-butyl (1R,3s,5S)-3-hydroxy-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (25 mg, 0.1 mmol) in MeOH (2 mL) and the resulting mixture stirred at 20° C. for 12 h. The reaction mixture was concentrated under reduced pressure to give (1R,3s,5S)-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octan-3-ol hydrochloride as a yellow oil (35 mg) which was used without further purification. LCMS m/z (ESI): 227.1 [M+H]+.
To a solution of compound (1R,3s,5S)-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octan-3-ol hydrochloride (30 mg, 0.1 mmol) in DCM (3 mL) was added DIPEA (60 μL, 0.3 mmol,) and 4-(difluoromethoxy) benzenesulfonyl chloride (41.6 mg, 0.2 mmol) at 0° C. The mixture was stirred at 20° C. for 3 h and quenched with water (10 mL). The reaction mixture was extracted with DCM (3×10 mL) and the combined organics washed with brine (3×10 mL), dried (Na2SO4), filtered, and evaporated to dryness in vacuo. The residue was purified by prep-HPLC (Welch Xtimate C18 25×150 mm, 5 μm; 33-63% MeCN/water (10 mM NH4HCO3)) to give (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-3-(morpholinomethyl)-8-azabicyclo[3.2.1]octan-3-ol as a white solid (14.5 mg, 29%). 1H NMR (400 MHZ, DMSO-d6) δ (ppm): 7.90 (d, J=8.8 Hz, 2H), 7.39-7.08 (m, 3H), 4.40 (s, 1H), 4.13 (br s, 2H), 3.50 (d, J=4.2 Hz, 2H), 2.43-2.40 (m, 6H), 2.22 (s, 2H), 2.07 (d, J=14.4 Hz, 2H), 1.72 (dd, J=4.0, 13.2 Hz, 2H), 1.44 (d, J=8.0 Hz, 2H), 1.26-1.12 (m, 2H). LCMS m/z (ESI): 433.1 [M+H]+.
DIPEA (70 μL, 0.4 mmol) was added to a mixture of 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine dihydrochloride (Intermediate 7, 31 mg, 0.1 mmol) and 4-(difluoromethoxy)-2,6-difluoro-benzenesulfonyl chloride (28 mg, 0.1 mmol) in DCM (2 mL) and the mixture stirred at room temperature for 2 h. The reaction was quenched with sat. aq. NaHCO3diluted with water and stirred at room temperature for 5 min. The organic phase was washed with water and evaporated to dryness in vacuo. The residue was triturated with small amount of MeCN to afford 4-(((1R,3s,5S)-8-((4-(difluoromethoxy)-2,6-difluorophenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine as a white solid (22 mg, 48%). 1H NMR (400 MHZ, CD3OD) δ (ppm): 7.33-6.81 (m, 3H), 4.33 (br d, J=2.3 Hz, 2H), 3.79-3.59 (m, 4H), 2.50-2.31 (m, 4H), 2.20-2.03 (m, 3H), 1.82-1.66 (m, 6H), 1.45-1.34 (m, 2H). LCMS m/z=453.1 [M+H]+.
4-(((1R,3s,5S)-8-((1,3-Dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine was prepared as a white solid (43 mg, 90%) from 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine dihydrochloride (Intermediate 7) and 2,5-dimethylpyrazole-3-sulfonyl chloride using an analogous method to that described for Example 35. Purified by column chromatography (12 g, SiO2, 7:1 EtOAc/EtOH). 1H NMR (400 MHZ, CD3OD) δ (ppm): 6.62 (s, 1H), 4.36-4.18 (m, 2H), 4.00 (s, 3H), 3.77-3.62 (m, 4H), 2.51-2.32 (m, 4H), 2.25 (s, 3H), 2.21-2.15 (m, 2H), 2.15-2.04 (m, 1H), 1.83-1.70 (m, 6H), 1.45-1.34 (m, 2H). LCMS m/z=369.2 [M+H]+.
4-(((1R,3r,5S)-8-((1,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine was prepared as a colorless oil (29 mg, 70%) from 4-(((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine dihydrochloride (Intermediate 8) and 2,5-dimethylpyrazole-3-sulfonyl chloride using an analogous method to that described for Example 35. 1H NMR (400 MHZ, CD3OD) δ (ppm): 6.60 (s, 1H), 4.30-4.17 (m, 2H), 3.97 (s, 3H), 3.70-3.62 (m, 4H), 2.40 (br d, J=4.5 Hz, 4H), 2.23 (s, 3H), 2.19-2.04 (m, 3H), 1.82-1.67 (m, 6H), 1.44-1.31 (m, 2H). LCMS m/z=369.2 [M+H]+.
4-(((1R,3r,5S)-8-((1,3-Dimethyl-1H-pyrazol-5-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine was prepared as a white solid (46 mg, 83%) from 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine dihydrochloride (Intermediate 7) and 3,5-dimethylisoxazole-4-sulfonyl chloride using an analogous method to that described for Example 35. 1H NMR (400 MHZ, CD3OD) δ (ppm): 4.26-4.13 (m, 2H), 3.76-3.59 (m, 4H), 2.63 (s, 3H), 2.48-2.28 (m, 7H), 2.18-2.14 (m, 2H), 2.12-1.98 (m, 1H), 1.91-1.63 (m, 6H), 1.35 (s, 2H). LCMS m/z=370.2 [M+H]+.
4-(((1R,3s,5S)-8-((4,6-Dimethylpyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine was prepared as a white solid (38 mg, 50%) from 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine dihydrochloride (Intermediate 7) and 4,6-dimethylpyridine-3-sulfonyl chloride using an analogous method to that described for Example 35. 1H NMR (400 MHZ, CD3OD) δ (ppm): 8.82 (s, 1H), 7.34 (s, 1H), 4.17 (br s, 2H), 3.71-3.60 (m, 4H), 2.64 (s, 3H), 2.57 (s, 3H), 2.38 (br s, 4H), 2.17-2.12 (m, 2H), 2.12-2.04 (m, 1H), 1.97-1.90 (m, 2H), 1.80-1.68 (m, 4H), 1.32 (br t, J=10.9 Hz, 2H). LCMS m/z=380.2 [M+H]+.
3-Hydroxybutanoic acid (193.20 mg, 1.86 mmol), tert-butyl (1R,3r,5S)-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (400 mg, 1.77 mmol) and NMI (507.90 mg, 6.19 mmol, 493.11 μL) were combined and dissolved in MeCN (15 mL). TCFH (743.87 mg, 2.65 mmol) was added in a single portion and the reaction was monitored by LCMS. After 12 h the mixture was diluted with water (15 mL) and extracted with EtOAc (20 mL×3). The combined organic phase was washed with brine (30 mL×3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The crude mixture was dissolved in MeOH (10 mL) and K2CO3 (488.54 mg, 3.53 mmol) was added. The resulting mixture was stirred for 1 h at 22° C. and then diluted with water (15 mL) and extracted with EtOAc (20 mL×3). The combined organic phase was washed with brine (30 mL×3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash column (MeOH in DCM=0%˜1%) to give the desired compound (380 mg, 69% yield) as a white solid. 1H NMR (400 MHZ, CDCl3) δ ppm 6.67 (d, J=7.2 Hz, 1H), 4.21-4.13 (m, 4H), 2.24-2.15 (m, 2H), 2.05-2.00 (m, 4H), 1.85-1.80 (m, 2H), 1.70-1.61 (m, 2H), 1.46 (s, 9H), 1.25 (d, J=6.0 Hz, 3H). LCMS m/z=257.1 [M+H-tBu]+.
A solution of tert-butyl (1R,3r,5S)-3-((3-hydroxybutyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate (380.00 mg, 1.22 mmol) in HCl/MeOH (4 M, 6 mL) was stirred at 20° C. for 1 h. Evaporation in vacuo gave crude N-((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)-3-hydroxybutanamide (300 mg, Hydrochloride) as a colorless oil. 1H NMR (400 MHZ, CD3OD) δ ppm 4.21-4.09 (m, 1H), 4.05-3.96 (m, 3H), 2.41-2.22 (m, 6H), 2.17-2.03 (m, 4H), 1.22 (d, J=6.0 Hz, 3H). LCMS m/z=212.9 [M+H]+.
To a solution of 4-(((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl)amino)butan-2-ol (300.00 mg, 1.21 mmol, Hydrochloride) and DIPEA (623.47 mg, 4.82 mmol, 840.26 μL) in DCM (6 mL) was added 4-(difluoromethoxy) benzenesulfonyl chloride (438.93 mg, 1.81 mmol, 288.20 μL) at 0˜5° C. The mixture was stirred at 20° C. for 2 h. The mixture was diluted with water (15 mL) and extracted with DCM (20 mL×3). The combined organic phase was washed with brine (40 mL×3), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash column (MeOH in DCM=0.5%˜2%) to give the desired compound (320 mg, 63% yield) as a white solid. 1H NMR (400 MHZ, CDCl3) δ ppm 7.91-7.85 (m, 2H), 7.25-7.17 (m, 2H), 6.80-6.40 (m, 2H), 4.24 (br s, 2H), 4.19-4.08 (m, 2H), 2.94 (br s, 1H), 2.37-2.18 (m, 4H), 1.85-1.72 (m, 6H), 1.22 (d, J=6.0 Hz, 3H). LCMS m/z=419.0 [M+H]+.
To a solution of N-((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)-3-hydroxybutanamide (100 mg, 238.97 μmol) in THF (8 mL) was added BH3·DMS (10 M, 95.59 μL) at 20° C. and the reaction mixture was stirred at 70° C. for 1 h under nitrogen. The mixture was quenched with methanol (10 mL) at 20° C., and then heated at 70° C. for 0.5 h. Concentration in vacuo gave the crude product which was purified by pre-HPLC (Column: Boston Prime C18 150*30 mm*5 μm, Condition: water (0.05% ammonia hydroxide v/v)-ACN, 50% ˜80%, Flow Rate (ml/min): 30)) to afford the title compound (111 mg, 37% yield) as a white solid. 1H NMR (400 MHZ, CD3OD) δ ppm 7.94-7.89 (m, 2H), 7.32-7.26 (m, 2H), 7.00 (t, J=73.2 Hz, 1H), 4.17 (br s, 2H), 3.90-3.80 (m, 1H), 2.89-2.81 (m, 1H), 2.66 (t, J=6.4 Hz, 2H), 2.18-2.03 (m, 2H), 1.97-1.86 (m, 2H), 1.79-1.69 (m, 2H), 1.64-1.48 (m, 2H), 1.47-1.41 (m, 2H), 1.14 (d, J=6.0 Hz, 3H). LCMS m/z=405.1 [M+H]+.
rac-4-(((1R,3s,5S)-8-((4-(Difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)butan-2-ol was prepared as a white solid (200 mg, 42%) following an analogous method to that described for Example 59, using tert-butyl (1R,3s,5S)-3-(3-hydroxybutanamido)-8-azabicyclo[3.2.1]octane-8-carboxylate and 3-Hydroxybutanoic acid in step 1. 1H NMR (400 MHZ, METHANOL-d4) δ=7.99-7.95 (m, 2H), 7.34 (d, J=8.8 Hz, 2H), 7.24-6.86 (m, 1H), 4.41 (br s, 2H), 3.93-3.84 (m, 1H), 3.60-3.47 (m, 1H), 3.16-3.09 (m, 2H), 2.19-2.14 (m, 2H), 1.86-1.78 (m, 3H), 1.72-1.64 (m, 3H), 1.58-1.52 (m, 2H), 1.23 (d, J=6.4 Hz, 3H). LCMS m/z=405.2 [M+H]+.
(1S,3s)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol and (1S,3s)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol were prepared following General Procedure C using (1s,3r)-3-(aminomethyl)cyclobutan-1-ol (HCl salt) as the secondary amine. The crude reaction mix was purified by flash silica gel chromatography (DCM/MeOH=10/1) to give the mixture of isomers as a white solid. Isomers were then separated by SFC (Column DAICEL CHIRALPAK IG (250 mm*30 mm, 10 μm); Condition: 0.1% NH3·H2O MEOH; Begin B: 45%; End B: 45%; Flow Rate (ml/min): 80) to give (1S,3s)-3-((((1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol (75.75 mg 6% yield) as a white solid and (1S,3s)-3-((((1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)methyl)cyclobutan-1-ol (237.56 mg, 19% yield) as a white solid.
(1R,3r,5S)-8-((4-(Difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3, 100 mg, 0.3 mmol) as hydrochloride salt and tetrahydro-4H-pyran-4-one (36 μL, 0.4 mmol) were taken up in DCM (2 mL). To this was added DIPEA (160 μL, 0.9 mmol), with stirring. After 10 min, acetic acid (52 μL, 0.9 mmol), was added with stirring. After 10 min, sodium triacetoxyborohydride (255 mg, 1.2 mmol) was added with stirring. Additional DCM (2 mL) was added, and the reaction was stirred overnight at room temperature. Reaction mixture was poured into saturated sodium bicarbonate, extracted with ethyl acetate, and the organics were evaporated. Residue was purified by silica gel chromatography using 0-100% 3:1 ethyl acetate/ethanol (+2% NH4OH) in heptanes as eluent to afford (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine (117 mg, 93%). 1H NMR (400 MHZ, CD3OD) δ (ppm): 7.85-7.99 (m, 2H), 7.26-7.33 (m, 2H), 6.79-7.21 (m, 1H), 4.21 (dt, J=4.83, 2.48 Hz, 2H), 3.93 (dt, J=10.10, 2.10 Hz, 2H), 3.40 (td, J=11.86, 2.13 Hz, 2H), 3.18 (tt, J=6.65, 3.51 Hz, 1H), 2.81 (tt, J=10.95, 4.11 Hz, 1H), 2.21 (dt, J=13.68, 5.96 Hz, 2H), 1.91-1.97 (m, 3H), 1.78-1.85 (m, 2H), 1.57-1.65 (m, 2H), 1.41-1.52 (m, 2H) 1.25-1.38 (m, 1H). LCMS m/z=417.2 [M+H]+.
(1R,3r,5S)-8-((4-(Difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine (40 mg, 0.1 mmol) was taken up in DMF (1 mL). To this was added sodium hydride (60% purity, 8 mg, 0.2 mmol) followed by iodomethane (24 μL, 0.4 mmol). The reaction was stirred at room temperature for 45 min to 1.5 h. The reaction was quenched by addition of saturated sodium bicarbonate solution, extracted with ethyl acetate, and the organics were evaporated. The residue was dissolved in DMSO purified by prep-HPLC (Waters SunFire Prep C18 5 μm OBD 30×100 mm; 5-55% MeCN in water (+TFA)) to afford (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine (trifluoroacetate salt) as a white solid (19 mg, 36%). LCMS m/z=431.3 [M+H]+, tR=1.38 min.
The title compound (trifluoroacetate salt) was prepared as a clear oil (18 mg, 38% over two steps) from (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 4 as hydrochloride salt) using an analogous procedure to that described for Example 65. LCMS m/z=431.3 [M+H]+, tR=1.39 min.
4-(((1R,3s,5S)-8-((4-(Difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine was prepared as a white solid (48 mg, 89%) from 4-(((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)methyl)morpholine dihydrochloride (Intermediate 7) and 4-(difluoromethoxy) benzenesulfonyl chloride using an analogous method to that described for Example 35, and purified by prep-HPLC (Welch Xtimate C18 25×150 mm, 5 μm; 33-63% MeCN/water (10 mM NH4HCO3) to afford the desired compound (48 mg, 89%). LCMS m/z=417.2 [M+H]+. tR=0.59 min.
(1R,5S)-8-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]heptan-6-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 6) and 2-oxaspiro[3.3]heptan-6-amine using an analogous method to that described for Example 19, purification by column chromatography (24 g SiO2, 20-50-100% EtOAc/EtOH (3/1) in heptane) afforded:
8-((4-(Difluoromethoxy)phenyl)sulfonyl)-N—((R)-tetrahydrofuran-3-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and (R)-tetrahydrofuran-3-amine using an analogous method to that described for Example 19, purification by column chromatography (12 g SiO2, 50-100% EtOAc in heptane) afforded a white powder after lyophilization (15 mg, 19%). 1H NMR (400 MHZ, CD3OD) δ (ppm): 7.86-8.00 (m, 2H), 7.31 (d, J=8.8 Hz, 2H), 6.76-7.24 (m, 1H), 4.19 (br s, 2H), 3.68-3.97 (m, 3H), 3.37-3.52 (m, 2H), 2.99 (br t, J=6.0 Hz, 1H), 1.96-2.21 (m, 5H), 1.60-1.78 (m, 3H), 1.34-1.53 (m, 2H). LCMS m/z=403.1 [M+H]+.
(1R,3r,5S)-8-((4-(Difluoromethoxy)phenyl)sulfonyl)-N-((3-fluorooxetan-3-yl)methyl)-8-azabicyclo[3.2.1]octan-3-amine (stereochemistry arbitrarily assigned) was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and (3-fluorooxetan-3-yl) methanamine using an analogous method to that described for Example 19, purification by column chromatography (12 g SiO2, 20-50-100% EtOAc/EtOH 3/1 in heptane) afforded a white powder after lyophilization (6.3 mg, 7%, more polar isomer, stereochemistry arbitrarily assigned). LCMS m/z=421.1 [M+H]+. tR=0.58 min.
(1R,3r,5S)-8-((4-(Difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-ylmethyl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from (1R,3r,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3) and oxetane-3-carbaldehyde using an analogous method to that described for Example 19, and purified by prep-HPLC (Welch Xtimate C18 25×150 mm, 5 μm; 33-63% MeCN/water (10 mM NH4HCO3) to afford the desired compound (48 mg, 76%). LCMS m/z=403.1 [M+H]+. tR=0.56 min.
8-((4-(Difluoromethoxy)phenyl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and tetrahydro-2H-pyran-4-amine using an analogous method to that described for Example 19, purified by prep-HPLC (Welch Xtimate C18 25×150 mm, 5 μm; 33-63% MeCN/water (10 mM NH4HCO3) to afford the desired compound (18 mg, 22%). LCMS m/z=417.2 [M+H]+. tR=0.58 min.
8-((4-(Difluoromethoxy)phenyl)sulfonyl)-N-(oxetan-3-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from 8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-one (Intermediate 5) and cyclobutanamine using an analogous method to that described for Example 19, purified by prep-HPLC (Welch Xtimate C18 25×150 mm, 5 μm; 33-63% MeCN/water (10 mM NH4HCO3) to afford the desired compound (61 mg, 67%). LCMS m/z=389.1 [M+H]+. tR=0.55 min.
(1R,3s,5S)-8-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-8-azabicyclo[3.2.1]octan-3-amine was prepared from (1R,3s,5S)-8-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 9) and tetrahydro-4H-pyran-4-one using an analogous method to that described for Example 19, purification by column chromatography (12 g SiO2, 50-100% EtOAc/EtOH 3/1 in heptane) afforded a white sticky solid (65 mg, 63%). 1H NMR (METHANOL-d4, 400 MHZ): δ (ppm) 8.55 (d, J=8.5 Hz, 1H), 7.84 (d, J=8.0 Hz, 1H), 4.28 (dd, J=4.0, 3.0 Hz, 2H), 3.94 (dd, J=11.0, 4.0 Hz, 2H), 3.40 (td, J=12.0, 2.0 Hz, 2H), 3.16 (tt, J=11.3, 5.5 Hz, 1H), 2.95 (s, 3H), 2.71-2.88 (m, 1H), 1.94-2.05 (m, 4H), 1.78-1.87 (m, 4H), 1.45-1.55 (m, 2H), 1.30-1.43 (m, 2H). LCMS m/z=434.2 [M+H]+
1-(((1R,3s,5S)-8-((4-(Difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)-2-methylpropan-2-ol was prepared from (1R,3s,5S)-8-((4-(difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 4) and 2,2-dimethyloxirane using an analogous method to that described for Example 17, purification by column chromatography (12 g SiO2, 100% EtOAc to 100% EtOAc/EtOH 3/1) afforded a white powder after lyophilization (30 mg, 74%). 1H NMR (400 MHZ, CD3OD) δ (ppm): 7.88-8.05 (m, 2H), 7.33 (d, J=7.3 Hz, 2H), 6.77-7.24 (m, 1H), 4.34 (br s, 2H), 3.07-3.24 (m, 1H), 2.72 (s, 2H), 2.08 (br d, J=13.1 Hz, 2H), 1.45-1.81 (m, 6H), 1.24 (d, J=1.0 Hz, 6H) LCMS m/z=405.1 [M+H]+.
1-(((1R,3r,5S)-8-((4-(Difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)-2-methylpropan-2-ol was prepared from (1R,3r,5S)-8-((4-(Difluoromethoxy)phenyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-amine (Intermediate 3) and 2,2-dimethyloxirane using an analogous method to that described for Example 17, purification by column chromatography (12 g SiO2, 100% EtOAc) afforded a white powder after lyophilization (12 mg, 30%). 1H NMR (400 MHZ, CD3OD) δ (ppm): 7.94 (dd, J=8.8, 1.0 Hz, 2H), 7.31 (d, J=7.8 Hz, 2H), 6.77-7.22 (m, 1H), 4.18 (br s, 2H), 2.89 (br t, J=5.8 Hz, 1H), 2.48 (s, 2H), 1.97-2.17 (m, 4H), 1.76 (br d, J=14.1 Hz, 2H), 1.34-1.55 (m, 2H), 1.20 (d, J=1.0 Hz, 6H). LCMS m/z=405.1 [M+H]+.
The EBP immunoaffinity (IA) LC-MS assay measures the potency of small molecule inhibitors of EBP by quantifying their concentration-dependent changes in the enzyme's substrate and product using liquid chromatography atmospheric pressure chemical ionization multiple reaction monitoring mass spectrometry (LC-APCI MRM MS). HEK293T cells were utilized as the source of EBP enzyme. The enzyme was incubated with the small molecule inhibitors at variable concentrations for 30 min. Deuterated form of EBP substrate, zymosterol-d5 (Avanti Polar Lipids, Cat #700068P-1 mg), was then added and the plate was incubated at 37° C. for 4 h. Finally, the sterol isomers were extracted and injected to LC-APCI MRM MS. MRM transition used for the quantification for both zymosterol and dihydrolathosterol (substrate and product of EBP enzymatic reaction, respectively) is 372.3-203.2, CE 30 and DP 80 in positive ion mode. Percent conversion of the zymosterol-d5 to dehydrolathosterol-d5 was used to derive IC50 curves. Tasin-1 (1′-[(4-Methoxyphenyl)sulfonyl]-4-methyl-1,4′-bipiperidine, CAS 792927-06-1) was used as the reference small molecule inhibitor.
Percent conversion versus the compound concentration data were fit to the following 4-parameter logistic model to generate IC50 curves:
This application claims the benefit of the filing date, under 35 U.S.C. § 119 (e), of U.S. Provisional Application No. 63/302,195, filed on Jan. 24, 2022, the entire contents of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2023/011327 | 1/23/2023 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63302195 | Jan 2022 | US |
